Formula C21H20N4O3 | Molar mass 376.4085 g/mol | |
 | ||
Significance of entinostat il 2 study in rcc
Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.
Contents
- Significance of entinostat il 2 study in rcc
- Phase iii trial of endocrine therapy plus entinostat placebo in patients with breast cancer
- Clinical trials
- References
Entinostat inhibits class I HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, respectively.
Syndax pharmaceuticals currently holds the rights to Entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools.
Phase iii trial of endocrine therapy plus entinostat placebo in patients with breast cancer
Clinical trials
There is an ongoing phase II trial studying the effect of entinostat on Hodgkin's lymphoma. It is in other phase II trials for advanced breast cancer (in combination with aromatase inhibitors) and for metastatic lung cancer (in combination with erlotinib). As of September 2013, the Food and Drug Administration is working with the industry to design phase III clinical trials. They seek to evaluate the application of Entinostat for the reduction, or prevention of, treatment resistance to aromatase inhibitors in hormone receptor positive breast cancer.